Randomized, Double-blind, Placebo-controlled, Multicenter Phase 3 Study to Assess the Efficacy, Safety And Immunogenicity of Vaccination With ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
Latest Information Update: 25 May 2025
At a glance
- Drugs JNJ-78901563 (Primary)
- Indications Escherichia coli infections
- Focus Registrational; Therapeutic Use
- Acronyms E.mbrace
- Sponsors Janssen Research & Development; Janssen Vaccines and Prevention B.V
Most Recent Events
- 09 Apr 2025 Status changed from discontinued to active, no longer recruiting.
- 28 Mar 2025 Planned End Date changed from 31 Jul 2027 to 27 Aug 2025.
- 28 Mar 2025 Planned primary completion date changed from 19 May 2025 to 27 Aug 2025.